|
|
Measurement
of tamoxifen-induced apoptosis in glioblastoma by cytometric bead analysis of
active caspase-3
Joy K. Zartman,
Nicholas K. Foreman, Andrew M. Donson and Julie M. Fleitz
University
of Colorado Health Sciences Center and Department
of Pediatric Oncology (N.K.F.,J.M.F.), The Children’s Hospital, Denver, CO,
USA
Pre-clinical trials of novel drugs for the
treatment of glioblastoma often use apoptosis as a measure of anti-tumor
effect.
Presently, there is no single reliable method to determine whether a cell is
apoptotic in glioblastoma.
The currently used methods for detecting apoptosis, including terminal
deoxynucleotidyl transferase nick-endlabeling, nuclear morphology, DNA
laddering, Annexin-V binding, and Western blotting, are subjective, difficult to
perform or difficult to quantify in glioblastoma.
Cytomeric bead array analysis for active caspase-3 is a recently developed
technique, which may allow rapid quantitation of apoptosis in
glioblastoma.
Tamoxifen (TAM), a drug used in treating breast cancer and more recently for
brain tumors, was used to induce apoptosis in human glioblastoma cell
lines.
This study showed that TAM-induced apoptosis via caspase-3 activation.
The results also revealed a time- and dose-dependent response of TAM-induced
caspase-3 activity in glioblastoma.
Cytometric bead array provides a rapid technique for measuring apoptosis and the
kinetics of caspase-3 activity in glioblastoma.
Key words: apoptosis,
caspase-3, cytometric bead analysis, glioblastoma, tamoxifen
© 2003 Kluwer Academic Publishers.
Printed in the Netherlands.
Source:
http://journals.kluweronline.com/article.asp?PIPS=5252507
|
